Eric Valeur
13Patents
3h-index
33Co-inventors
56Inventor score
Filing activity: Jan 15, 2009 → Apr 15, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8618158B2 | Therapeutic agents | Chemistry; Metallurgy | 10 | Active |
| US9358222B2 | Therapeutic agents | Chemistry; Metallurgy | 9 | Active |
| US10414726B2 | Therapeutic agents | Chemistry; Metallurgy | 6 | Active |
| US9452990B2 | Complement pathway modulators and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US8835634B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | Chemistry; Metallurgy | 1 | Active |
| US8415352B2 | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | Chemistry; Metallurgy | 1 | Active |
| US8486964B2 | Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | Human Necessities | 1 | Active |
| US8609689B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | Human Necessities | 0 | Active |
| US8815859B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US12115225B2 | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US9233937B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | Chemistry; Metallurgy | 0 | Active |
| US8642617B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | Human Necessities | 0 | Active |
| US8178556B2 | Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.